

IMMUNOMEDICS INC  
Form 8-K  
August 07, 2009

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): August 4, 2009**

**Immunomedics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-12104**  
(Commission File Number)

**61-1009366**  
(IRS Employer  
Identification No.)

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

**300 American Road, Morris Plains, New Jersey**  
(Address of Principal Executive Offices)

**(973) 605-8200**

**07950**  
(Zip Code)

(Registrant's telephone number, including area code)

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**Item 1.01. Entry into a Material Definitive Agreement.**

On August 4, 2009, Immunomedics, Inc., a Delaware corporation (the Company ), received a letter, dated July 30, 2009, from UCB, S.A. ( UCB ) stating that UCB has identified a third party manufacturer for epratuzumab and therefore relieved the Company of its obligation to supply to UCB Licensed Product (as defined in that certain Development, Collaboration and License Agreement, dated as of May 9, 2006, between the Company and UCB (the Agreement )) pursuant to Section 4.3 of the Agreement for use in clinical trials for systemic lupus erythematosus. All other terms of the Agreement remain in effect.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Gerard G. Gorman  
Name: Gerard G. Gorman  
Title: Senior Vice President, Finance and Business  
Development and Chief Financial Officer

Date: August 7, 2009